Russell Investments Group Ltd. Raises Holdings in LeMaitre Vascular Inc (NASDAQ:LMAT)

Russell Investments Group Ltd. raised its stake in LeMaitre Vascular Inc (NASDAQ:LMAT) by 21.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 177,533 shares of the medical instruments supplier’s stock after acquiring an additional 31,575 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.92% of LeMaitre Vascular worth $6,877,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Conestoga Capital Advisors LLC boosted its holdings in LeMaitre Vascular by 15.4% in the third quarter. Conestoga Capital Advisors LLC now owns 1,607,000 shares of the medical instruments supplier’s stock valued at $62,255,000 after purchasing an additional 214,409 shares during the last quarter. First Trust Advisors LP purchased a new position in LeMaitre Vascular in the third quarter valued at about $214,000. Summit Creek Advisors LLC boosted its holdings in LeMaitre Vascular by 37.0% in the third quarter. Summit Creek Advisors LLC now owns 292,814 shares of the medical instruments supplier’s stock valued at $11,344,000 after purchasing an additional 79,053 shares during the last quarter. Curbstone Financial Management Corp purchased a new position in LeMaitre Vascular in the third quarter valued at about $815,000. Finally, Northern Trust Corp boosted its holdings in LeMaitre Vascular by 3.1% in the second quarter. Northern Trust Corp now owns 256,951 shares of the medical instruments supplier’s stock valued at $8,603,000 after purchasing an additional 7,700 shares during the last quarter. 81.54% of the stock is owned by institutional investors.

In other news, Director Michael H. Thomas sold 20,000 shares of the stock in a transaction that occurred on Tuesday, October 30th. The stock was sold at an average price of $27.93, for a total transaction of $558,600.00. Following the sale, the director now directly owns 20,000 shares in the company, valued at approximately $558,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.30% of the stock is currently owned by corporate insiders.

Shares of NASDAQ LMAT opened at $26.60 on Thursday. LeMaitre Vascular Inc has a 52-week low of $25.63 and a 52-week high of $41.28. The company has a market cap of $546.14 million, a price-to-earnings ratio of 30.93, a PEG ratio of 2.20 and a beta of 1.00.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.21. The firm had revenue of $24.17 million for the quarter, compared to analysts’ expectations of $26.06 million. LeMaitre Vascular had a return on equity of 18.07% and a net margin of 20.52%. Equities research analysts expect that LeMaitre Vascular Inc will post 1.02 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 6th. Stockholders of record on Tuesday, November 20th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 1.05%. The ex-dividend date of this dividend is Monday, November 19th. LeMaitre Vascular’s payout ratio is 32.56%.

A number of brokerages recently commented on LMAT. BidaskClub raised LeMaitre Vascular from a “sell” rating to a “hold” rating in a report on Friday, September 28th. Roth Capital downgraded LeMaitre Vascular from a “buy” rating to a “neutral” rating and increased their price target for the company from $38.00 to $39.00 in a report on Tuesday, October 2nd. Zacks Investment Research cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Wednesday, September 26th. Barrington Research upgraded LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $34.00 price objective on the stock in a research note on Monday, October 8th. Finally, Canaccord Genuity cut their price objective on LeMaitre Vascular from $40.00 to $32.00 and set a “hold” rating on the stock in a research note on Monday, October 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $35.86.

COPYRIGHT VIOLATION WARNING: This article was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.baseballdailydigest.com/news/2018/12/06/russell-investments-group-ltd-has-6-88-million-holdings-in-lemaitre-vascular-inc-lmat.html.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: Yield Curve

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply